Clinical trials: completed, sponsored by Dana-Farber Cancer Institute
Lymphoma, Neuroblastoma
Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma
This research study is evaluating a novel drug called CUDC-907 as a possible treatment for resistant (refractory) pediatric solid tumors (including neuroblastoma), lymphoma, or brain tumors.
- Conditions
- Lymphoma, Neuroblastoma, Brain Tumor, Solid Tumor
- Trial name
- NCT02909777
- Testing
- CUDC-907
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa
This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer.
- Trial name
- NCT01796197
- Testing
- Trastuzumab, Pertuzumab, Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Dana-Farber Cancer Institute
Cancer Survivors, Insomnia
Sleep Treatment Education Program-1 (STEP-1)
The purpose of the study is to learn if single session online education programs can help improve cancer survivors' sleep.
- Trial name
- NCT05519982
- Testing
- Sleep Treatment Education Program (STEP-1), Enhanced Usual Care
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Dana-Farber Cancer Institute
Blastic Plasmacytoid Dendritic Cell Neoplasm
Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
This research study is studying a drug as a possible treatment for BPDCN. The intervention involved in this study is: Venetoclax
- Trial name
- NCT03485547
- Testing
- Venetoclax
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
The purpose of this research study is to determine how well neratinib works in treating breast cancer that has spread to the brain.
- Trial name
- NCT01494662
- Testing
- HKI-272, Surgical Resection, Capecitabine
- Where
- 18 sites in United States
- Volunteers
- 140 people
- Sponsor
- Dana-Farber Cancer Institute
HPV Infection, HPV Positive Oropharyngeal Squamous Cell Carcinoma
The SPOT-HPV Study
The purpose of this research is to evaluate a new test for oral HPV DNA in saliva ('oral rinse test').
- Trial name
- NCT05524025
- Testing
- Salivary TTMV-HPV DNA Test, Blood TTMV-HPV DNA Test
- Where
- 2 sites in United States
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
Multiple Myeloma
Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma
This research study is evaluating a combination of three drugs called lenalidomide, subcutaneous (injection under the skin) bortezomib, and dexamethasone (RVD) as a possible treatment for multiple myeloma.
- Trial name
- NCT02441686
- Testing
- Bortezomib, Lenalidomide, Dexamethasone
- Where
- 8 sites in United States
- Volunteers
- 46 people
- Sponsor
- Dana-Farber Cancer Institute
Esophageal Cancer, Gastric Cancer
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
The purpose of this study is to determine the safety and effectiveness of a combination of chemotherapy, capecitabine and oxaliplatin, plus the antibodies bevacizumab and trastuzumab.
- Trial name
- NCT01191697
- Testing
- bevacizumab, trastuzumab, oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Dana-Farber Cancer Institute
Glioblastoma, Recurrent Glioblastoma
ASP8374 + Cemiplimab in Recurrent Glioma
This study is looking at the safety and efficacy of the drug combination of ASP8374 with cemiplimab in people with recurrent malignant glioma.
- Trial name
- NCT04826393
- Testing
- ASP8374, cemiplimab
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- Dana-Farber Cancer Institute
Other Cancer
Advance Care Planning: Promoting Effective and Aligned Communication in the Elderly
In this research study, the investigators are working to help oncologists better serve patients by delivering more patient-centered, goal-concordant care that may improve health care delivery.
- Trial name
- ACP-PEACE (NCT03609177)
- Testing
- Clinician Communication Skills Training, Advance Care Planning (ACP) Decisions Videos Decisions Aids, Video Declarations (ViDec)
- Where
- 4 sites in United States
- Volunteers
- 13,800 people
- Sponsor
- Dana-Farber Cancer Institute
Acute Lymphoblastic Leukemia
A Study in Adults With Untreated Acute Lymphoblastic Leukemia
The purpose of this study is to determine the safety and optimal dosing of L-asparaginase in adult patients with acute lymphoblastic leukemia (ALL) between the ages of 18 and 50 years.
- Trial name
- NCT00136435
- Testing
- prednisone, doxorubicin, vincristine
- Where
- 12 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Dana-Farber Cancer Institute
Flat Epithelia Atypia, Intraductal Papilloma Without Atypia
The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed With Intraductal Papilloma Without Atypia or Flat Epithelial Atypia by Core Needle Biopsy
This research study is studying a surgical intervention to rule out the presence of cancer in participants that have been diagnosed with flat epithelial atypia (FEA) or intraductal papilloma without atypia (IPWA) by core needle…
- Trial name
- NCT02489617
- Testing
- Pathologic evaluation of excised tissue
- Where
- 18 sites in United States
- Volunteers
- 246 people
- Sponsor
- Dana-Farber Cancer Institute
Triple Negative Breast Cancer
Cisplatin vs Paclitaxel for Triple Negative Breast Cancer
This is a phase II study randomizing patients with stage I with T1 > 1.5 cm, stage II or III triple negative breast cancer (TNBC) to preoperative cisplatin versus paclitaxel.
- Trial name
- NCT01982448
- Testing
- Cisplatin, Paclitaxel
- Where
- 20 sites in United States
- Volunteers
- 147 people
- Sponsor
- Dana-Farber Cancer Institute
Hematologic Malignancy
Home Transfusion for HEME
The purpose of the research is to assess the feasibility and acceptability of a home blood transfusion program for patients with hematologic malignancies who need blood transfusions
- Trial name
- NCT05509439
- Testing
- Home Transfusion Program Components
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
Melanoma
Dendritic Cell Activating Scaffold in Melanoma
This research study is a Phase I clinical trial. Phase I clinical trials test the safety of investigational melanoma vaccines. Phase I studies also try to define the appropriate dose of the investigational vaccine, in this case…
- Trial name
- NCT01753089
- Testing
- WDVAX
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Dana-Farber Cancer Institute
Gynecologic Cancer
The HOPE Trial and the SMART Study
This research study is evaluating a new smartphone application named the "Helping Our Patients Excel (HOPE)" app with a Fitbit device. The SMART Study is a sub-study of the HOPE Trial.
- Trial name
- NCT03022032
- Testing
- Fitbit Zip, HOPE App, Standard of Care
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Dana-Farber Cancer Institute
Sarcoma, Liposarcoma
A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
This research study is studying a combination of drugs (chemotherapy + Immunotherapy) as a possible treatment for liposarcoma, leiomyosarcoma, or undifferentiated pleomorphic sarcoma that has spread and has not responded to…
- Conditions
- Sarcoma, Liposarcoma, Leiomyosarcoma, Undifferentiated Pleomorphic Sarcoma
- Trial name
- NCT03899805
- Testing
- Eribulin, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 57 people
- Sponsor
- Dana-Farber Cancer Institute
Other Cancer, Gastrointestinal Cancer
Symptom Management Implementation of Patient Reported Outcomes in Oncology
Deficits in the management of common symptoms cause substantial morbidity for cancer patients.Because the health care delivery system is structured to be reactive and not proactive, there are missed opportunities to optimize…
- Conditions
- Other Cancer, Gastrointestinal Cancer, Thoracic Cancer, Gynecologic Cancer
- Trial name
- SIMPRO (NCT03850912)
- Testing
- Stakeholder Survey (Control Period), Stakeholder Survey (Intervention Period), Qualitative Interview
- Where
- 6 sites in United States
- Volunteers
- 42,808 people
- Sponsor
- Dana-Farber Cancer Institute
Smoldering Multiple Myeloma
Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
This research study is evaluating a new drug called "ixazomib" as a possible treatment for Smoldering Multiple Myeloma.
- Trial name
- NCT02916771
- Testing
- Ixazomib, Lenalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Dana-Farber Cancer Institute
Clear Cell Renal Cell Carcinoma
ABEMA Alone or in COMBO With MK-6482
This research study will assess whether abemaciclib alone or in combination with MK-6482 are safe and effective in slowing down the growth of clear cell renal cell carcinoma (ccRCC).
- Trial name
- NCT04627064
- Testing
- Abemaciclib, MK-6482
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Dana-Farber Cancer Institute